16055-12-2 Usage
Uses
Used in Pharmaceutical Industry:
2,5-dihydrophenylalanine is used as a therapeutic agent for the treatment of Parkinson's disease, as it can cross the blood-brain barrier and be converted into dopamine by the enzyme DOPA decarboxylase, thereby increasing dopamine levels in the brain.
Used in Neurological Disorders Research:
2,5-dihydrophenylalanine is used as a research compound for studying its potential therapeutic effects in other conditions such as depression and attention deficit hyperactivity disorder (ADHD), given its role in neurotransmission and mood regulation.
Check Digit Verification of cas no
The CAS Registry Mumber 16055-12-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,0,5 and 5 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 16055-12:
(7*1)+(6*6)+(5*0)+(4*5)+(3*5)+(2*1)+(1*2)=82
82 % 10 = 2
So 16055-12-2 is a valid CAS Registry Number.
InChI:InChI=1/C9H13NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-2,5,8H,3-4,6,10H2,(H,11,12)/t8-/m0/s1
16055-12-2Relevant academic research and scientific papers
Ozonolysis of (cyclohexa-1,4-dienyl)-L-alanine. An approach to the synthesis of new unnatural aminoacids. X-Ray molecular structure of 2-hydroxy-7-methyl-3-phenylpyrazolopyrimidine
Zvilichovsky, Gury,Gurvich, Vadim
, p. 2509 - 2516 (2007/10/02)
The aromatic ring in L-phenylalanine was transformed into isoxazolyl, N-phenylpyrazolyl, and the bicyclic pyrazolopyrimidinyl groups, by a combination of Birch reduction and ozonolysis, followed by condensation with the relevant binucleophiles.The ozonolysis was carried out on the N-acylated esters of cyclohexa-1,4-dienylalanine.The resulting N-acylated esters of heterocyclic alanine derivatives were obtained without isolation of the ozonolysis products. 4-Phenylpyrazolidine-3,5-dione was used as a 'hydrazine donor' in the construction of pyrazolyl group, as direct condensation with hydrazine was successful.
